Search PubMed⌕ Search

Biomedical subjects

M A El-Gendi

Publications and source records attributed to M A El-Gendi.

7 recordsLinked to original sources
PubMed1982

Pharmacotherapeutics of prostaglandin E2 and 15 (S) 15-methyl prostaglandin F2 alpha in chronic schistosomal bladder ulcer: a clinico-endoscopic study.

The pharmacotherapeutic effects of prostaglandin E2 (PGE2) and 15 (S) 15-methyl PGF2 alpha given by different routes of administration, were studied in 20 normal persons and 100 patients with chronic schistosomal bladder ulcer in comparison to normal saline and antimony dimercaptosuccinate drug. Prostaglandins produced a rapid significant amelioration in the ulcer symptom complex with a good percentage of ulcer disappearance on cystoscopy, while the antimony dimercaptosuccinate treated group showed a less early response which improved with follow up. This was in contrast to prostaglandins which showed relapse in the symptom-complex in some cases after a follow up period of 2 months. The combined use of schistosomicidal drugs together with, or followed by, prostaglandins might give better results.

Administration, Oral↗
PubMed1980

Effect of histamine and histamine antagonists on portal blood pressure in patients with hepatosplenic schistosomiasis.

1 Histamine injection via the cannulated portal vein significantly raised the portal pressure in normal volunteers. This elevation was reversed by an H1-receptor blocker but not an H2-receptor blocker. When an H1-receptor blocker was injected first followed by histamine, no significant change in portal pressure was obtained. On the other hand, an H2-receptor blocker failed to antagonize the effect of histamine. 2 Histamine injection induced a non-significant increase in the portal pressure in patients with schistosomal portal hypertension, but when an H1-receptor blocker was injected a significant drop in the portal pressure was obtained. No similar effect was found after an H2-receptor blocker injection. 3 Angiographic study showed that histamine induced intrahepatic portal vasoconstriction in the normal controls. A similar change was obtained in the schistosomal group, particularly on the periportal neovascular formation. 4 In the light of the present study, it is suggested that histamine may contribute in part to the physiopathologic changes that lead to portal hypertension in hepatosplenic schistosomiasis. H1-receptor antagonists may have a role in the treatment of portal hypertension, particularly in bleeding varices.

Adult↗
PubMed1977

Contrasting haemodynamic patterns of portal hypertension in hepatosplenic schistosomiasis.

18 cases of hepatosplenic schistosomiasis taken at random were studied. The transumbilical portal pressure, the trans-splenic portal pressure, the occluded thoracic duct pressure, and thoracic duct lymph flow were measured simultaneously before and after splenectomy. The findings were correlated with the clinical data, liver pathology, and operative findings. The transumbilical portal pressure-trans-splenic portal pressure gradient was found of significant importance. It was considered positive when the transumbilical portal pressure was higher than the trans-splenic portal pressure, in such cases the primary generating factor of portal hypertension is most probably of hepatic origin (post or presinusoidal obstruction; organic or functional). The gradient was considered negative when the transumbilical portal pressure was lower than the trans-splenic portal pressure; in such cases the primary generating factor of portal hypertension is most probably of splenic origin (hyperdynamic spleen) or in the portal vein (thrombosis). A significant correlation was found between the type of this gradient, the thoracic duct lymph flow and the clinico-pathological state. The thoracic duct flow was highest in the non-bleeders. Definite contrasting haemodynamic patterns were found between bleeders and non-bleeders. The bearing of these contrasting patterns on the selection of the operative procedure in the treatment of portal hypertension is suggested.

Blood Pressure↗
PubMed1976

Beta-adrenergic receptors and the effect of beta-adrenergic blocking agent propranolol on histamine and reserpine stimulated gastric acid secretion in man: normals and duodenal ulcer cases.

The effects of the beta adrenergic stimulant drug, "Nylidrin", and the beta adrenergic blocking agent, "Propranolol", on human basal gastric acid secretion were studied in 20 healthy volunteer subjects and 10 chronic D.U. cases. Nylidrin increased gastric acid secretion and volume. All effects of nylidrin were blocked by prior administration of beta adrenergic inhibitor propranolol. Propranolol diminished both acid secretion and volume in both normal and D.U. cases. The presence of beta adrenergic receptors in the human stomach was suggested. The effects of beta adrenergic blocking agent propranolol on gastric secretion, stimulated with histamine, were studied in 10 normal subjects and 10 cases of chronic duodenal ulcer patients. Pretreatment with propranolol produced a signigicant depression of the 90 minute acid response to histamine in both volume and acidity in normals and duodenal ulcer cases. It is concluded that propranolol has an antisecretory effect, not only on basal gastric secretion but also on histamine stimulated secretion in man. Reserpine stimulated gastric acid secretion and volume in normals but showed no similar effect in D.U. cases. After pretreatment with propranolol it reduces the gastric acid secretion and volume in normals and D.U. cases.

Adult↗